{"disease":{"id":"secondary-progressive-multiple-sclerosis","name":"Secondary progressive multiple sclerosis","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":4,"pipeline_drug_count":0,"trial_count":2},"drugs":{"marketed":[{"drug_id":"humax-cd20","indication_name":"Secondary progressive multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Arzerra","generic_name":"HuMax-CD20","company_name":"Glaxo Grp Ltd","drug_phase":"discontinued","molecular_target":"B-lymphocyte antigen CD20","drug_class":"CD20-directed Cytolytic Antibody","quality_score":null,"revenue":"3198","mechanism":"Arzerra works by binding to the CD20 protein on B cells, marking them for destruction by the immune system."},{"drug_id":"siponimod","indication_name":"Secondary progressive multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mayzent","generic_name":"SIPONIMOD","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Sphingosine 1-phosphate receptor 1","drug_class":"Sphingosine 1-phosphate Receptor Modulator [EPC]","quality_score":10,"revenue":"1068","mechanism":"Mayzent works by binding to the sphingosine 1-phosphate receptor 1, which helps to reduce inflammation and slow disease progression."},{"drug_id":"mayzent","indication_name":"Secondary progressive multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Mayzent","company_name":"Novartis Pharmaceuticals","drug_phase":"discontinued","molecular_target":"Sphingosine 1-phosphate receptor 2, Sphingosine 1-phosphate receptor 1, Sphingosine 1-phosphate receptor 3","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"arzerra","indication_name":"Secondary progressive multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Arzerra","company_name":"GlaxoSmithKline","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD20","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06372145","title":"A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2500,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT01665144","title":"Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1651,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT07225504","title":"A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1275,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04411641","title":"Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1131,"lead_sponsor_name":"Sanofi","has_results":true},{"nct_id":"NCT03387670","title":"Multiple Sclerosis-Simvastatin Trial 2","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":964,"lead_sponsor_name":"University College, London","has_results":false},{"nct_id":"NCT01416181","title":"A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":889,"lead_sponsor_name":"Biogen","has_results":true},{"nct_id":"NCT07168694","title":"A Real-world Study About the Impact of Siponimod Treatment on Secondary Progressive Multiple Sclerosis Patients in Russia","phase":"","overall_status":"COMPLETED","enrollment_count":606,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04688788","title":"Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":600,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT04593927","title":"Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients","phase":"","overall_status":"COMPLETED","enrollment_count":451,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT01910259","title":"MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":445,"lead_sponsor_name":"University College, London","has_results":false},{"nct_id":"NCT05826028","title":"Mayzent (Siponimod) Onboarding of Secondary Progressive Multiple Sclerosis (SPMS) Patients With MSGo","phase":"","overall_status":"COMPLETED","enrollment_count":368,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04940065","title":"Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen","phase":"","overall_status":"COMPLETED","enrollment_count":367,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06526000","title":"Study to Assess Changes in Immunoglobulins in Patients With Relapsing Multiple Sclerosis Treated With Anti-CD20 Therapies","phase":"","overall_status":"COMPLETED","enrollment_count":326,"lead_sponsor_name":"Novartis","has_results":false},{"nct_id":"NCT06588387","title":"A Real-world Study to Assess the Use of Siponimod in Spain to Treat Patients With Secondary Progressive Multiple Sclerosis","phase":"","overall_status":"COMPLETED","enrollment_count":210,"lead_sponsor_name":"Novartis","has_results":false},{"nct_id":"NCT05961644","title":"Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS).","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":188,"lead_sponsor_name":"Institute of Psychiatry and Neurology, Warsaw","has_results":false},{"nct_id":"NCT03283826","title":"Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":134,"lead_sponsor_name":"Atara Biotherapeutics","has_results":false},{"nct_id":"NCT05376579","title":"Impact of Mayzent on aSPMS Patients in a Long-term NIS in Italy","phase":"","overall_status":"COMPLETED","enrollment_count":134,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05893225","title":"Metformin Add-on Clinical Study in Multiple Sclerosis to Evaluate Brain Remyelination And Neurodegeneration","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"University Hospital, Antwerp","has_results":false},{"nct_id":"NCT06395909","title":"A Study to Assess the Effectiveness and Safety of Mayzent in Chinese Patients With Relapsing Forms of Multiple Sclerosis","phase":"","overall_status":"COMPLETED","enrollment_count":113,"lead_sponsor_name":"Novartis","has_results":false},{"nct_id":"NCT02988401","title":"Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":105,"lead_sponsor_name":"Johns Hopkins University","has_results":true},{"nct_id":"NCT05327322","title":"Functional Outcomes From Diets in Multiple Sclerosis","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":100,"lead_sponsor_name":"University of Alabama at Birmingham","has_results":false},{"nct_id":"NCT03315923","title":"Comparison of Clinical Effects of Rituximab and Glatiramer Acetate in Secondary Progressive Multiple Sclerosis Patients","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":84,"lead_sponsor_name":"Isfahan University of Medical Sciences","has_results":false},{"nct_id":"NCT07355387","title":"Home Based Functional Balance Intervention for Multiple Sclerosis","phase":"NA","overall_status":"RECRUITING","enrollment_count":75,"lead_sponsor_name":"University of Illinois at Chicago","has_results":false},{"nct_id":"NCT03783416","title":"SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":72,"lead_sponsor_name":"Queen Mary University of London","has_results":false},{"nct_id":"NCT05496881","title":"Exercise Effects in Multiple Sclerosis","phase":"NA","overall_status":"UNKNOWN","enrollment_count":69,"lead_sponsor_name":"University of Regina","has_results":false},{"nct_id":"NCT02208050","title":"A Study of the Effectiveness of Fampridine in Improving Upper Limb Function in MS","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":64,"lead_sponsor_name":"University College Dublin","has_results":true},{"nct_id":"NCT02305264","title":"Imaging of Intracerebral Inflammation in MS","phase":"NA","overall_status":"COMPLETED","enrollment_count":61,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT01950234","title":"ACTH in Progressive Forms of MS","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":59,"lead_sponsor_name":"University of Minnesota","has_results":true},{"nct_id":"NCT06890923","title":"Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":55,"lead_sponsor_name":"Tiziana Life Sciences LTD","has_results":false},{"nct_id":"NCT06961383","title":"Study of NG01 Cell Therapy in Secondary Progressive Multiple Sclerosis","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":45,"lead_sponsor_name":"NeuroGenesis Ltd.","has_results":false},{"nct_id":"NCT04792567","title":"Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC)","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":41,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT03471338","title":"Neuropsychological Management of Multiple Sclerosis: Benefits of a Computerised Semi-autonomous At-home Cognitive Rehabilitation Programme","phase":"NA","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"University Hospital, Caen","has_results":false},{"nct_id":"NCT03896217","title":"Simvastatin in Secondary Progressive Multiple Sclerosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"University College, London","has_results":true},{"nct_id":"NCT06677710","title":"IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis","phase":"PHASE1","overall_status":"SUSPENDED","enrollment_count":34,"lead_sponsor_name":"Indapta Therapeutics, INC.","has_results":false},{"nct_id":"NCT03282760","title":"Safety Study of Human Neural Stem Cells Injections for Secondary Progressive Multiple Sclerosis Patients","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Casa Sollievo della Sofferenza IRCCS","has_results":false},{"nct_id":"NCT05349474","title":"Metformin Treatment in Progressive Multiple Sclerosis","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":23,"lead_sponsor_name":"University of California, Los Angeles","has_results":false},{"nct_id":"NCT07222956","title":"A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":20,"lead_sponsor_name":"Moein Amin","has_results":false},{"nct_id":"NCT03493841","title":"Comparing Tolerability and Absorption of Racemic and R-lipoic Acid in Progressive Multiple Sclerosis","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Rebecca Spain","has_results":false},{"nct_id":"NCT04239664","title":"Acceptance Based Telephone Support When Transitioning to SPMS","phase":"NA","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"University of Nottingham","has_results":false},{"nct_id":"NCT05357833","title":"Novel Imaging Markers in SPMS","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":11,"lead_sponsor_name":"University of Utah","has_results":false},{"nct_id":"NCT03935529","title":"Behavioural Activation for Low Mood in Multiple Sclerosis","phase":"NA","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"University of Lincoln","has_results":false},{"nct_id":"NCT04925557","title":"Study to Assess the Efficacy of Mayzent on Microglia in Secondary Progressive Multiple Sclerosis","phase":"PHASE2, PHASE3","overall_status":"TERMINATED","enrollment_count":8,"lead_sponsor_name":"State University of New York at Buffalo","has_results":true},{"nct_id":"NCT02495766","title":"Autologous Mesenchymal Stromal Cells for Multiple Sclerosis","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":8,"lead_sponsor_name":"Banc de Sang i Teixits","has_results":false},{"nct_id":"NCT04895202","title":"Swiss Study of the Impact of Mayzent on SPMS Patients in a Long-term Non-interventional Study","phase":"","overall_status":"TERMINATED","enrollment_count":8,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06360861","title":"Evaluate the Safety and Feasibility of Allogeneic Mesenchymal Stem Cells in Patients With Multiple Sclerosis","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":5,"lead_sponsor_name":"Tehran University of Medical Sciences","has_results":false},{"nct_id":"NCT03696485","title":"Study to Assess the Safety and Efficacy of an IT Administration of SCM-010 in SPMS","phase":"PHASE1, PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Stem Cell Medicine Ltd.","has_results":false},{"nct_id":"NCT06802328","title":"Intermediate-Size Patient Population Expanded Access: Foralumab in Non-Active Secondary Progressive MS Patients","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Tiziana Life Sciences LTD","has_results":false}],"total":47},"guidelines":[],"source":"Drug Landscape verified database"}